Azitra, Inc. (AZTR)

US — Healthcare Sector
Peers: ONCO  JSPR  SPRC  SLXN  INDP  SCNI  SLRX  REVB  LIPO  ENVB 

Automate Your Wheel Strategy on AZTR

With Tiblio's Option Bot, you can configure your own wheel strategy including AZTR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AZTR
  • Rev/Share 1.8196
  • Book/Share 553.4999
  • PB 0.0006
  • Debt/Equity 0.2192
  • CurrentRatio 1.2347
  • ROIC -4.9484

 

  • MktCap 3642142.0
  • FreeCF/Share -2027.6058
  • PFCF -0.0004
  • PE -0.0003
  • Debt/Assets 0.1162
  • DivYield 0
  • ROE -5.1685

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
AZTR
Published: November 24, 2025 by: PRNewsWire
Sentiment: Neutral

BRANFORD, Conn. , Nov. 24, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,687,500 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 4,687,500 shares of common stock, in a private placement priced at a premium to market under NYSE rules (the "Offering").

Read More
image for news Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
AZTR
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral

BRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the dosing of the first patient in its Phase 1/2 clinical trial of ATR04-484, a topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash.

Read More
image for news Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In Focus
AZTR, IVV, SPLG, SPXL, SPY, SSO, UPRO, VOO, ZM
Published: August 22, 2025 by: Benzinga
Sentiment: Positive

U.S. stock futures rose on Friday following Thursday's declines. Futures of major benchmark indices were higher.

Read More
image for news Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In Focus

About Azitra, Inc. (AZTR)

  • IPO Date 2023-06-20
  • Website https://azitrainc.com
  • Industry Biotechnology
  • CEO Francisco D. Salva
  • Employees 12
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.